Valuation: VolitionRx Limited

Market Cap 3.69M 3.22M 3.04M 2.76M 5.17M 354M 5.19M 36.42M 14.05M 180M 13.87M 13.56M 580M P/E 2026 *
-0.13x
P/E 2027 * -0.26x
Enterprise Value 3.69M 3.22M 3.04M 2.76M 5.17M 354M 5.19M 36.42M 14.05M 180M 13.87M 13.56M 580M EV / Sales 2026 *
1.36x
EV / Sales 2027 * 0.4x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day-8.74%
1 week-16.18%
Current month-40.08%
1 month-46.73%
3 months-81.82%
6 months-93.16%
Current year-94.91%
1 week 0.24
Extreme 0.2407
0.31
1 month 0.24
Extreme 0.2407
0.72
Current year 0.24
Extreme 0.2407
7.73
1 year 0.24
Extreme 0.2407
14.8
3 years 0.24
Extreme 0.2407
24.6
5 years 0.24
Extreme 0.2407
82.8
10 years 0.24
Extreme 0.2407
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/3/26
Concord International, Inc.
OtherCompany 0 0% -
17/3/26 Tax

Executive/Senior Manager

5,251 0.0039%
17/3/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-8.74%-16.18%-98.09%-98.76% 3.69M
+2.30%+19.19%+400.00%+88.77% 4.64B
+0.21%+18.22%+114.15%+426.89% 4.57B
-1.91%-2.63%+16.67%+65.06% 3.2B
-0.83%+7.10%+268.95%+571.20% 2.78B
+6.41%+10.68%-21.68%-25.59% 2.27B
+10.59%+13.36%+53.68% - 1.84B
+0.30%+7.13%+27.07%+57.21% 1.11B
-4.13%+6.74%+158.15%-31.33% 1.04B
-3.88%-4.48%-19.56%+36.87% 568M
Average +0.03%+5.60%+89.93%+121.14% 2.2B
Weighted average by Cap. +1.41%+10.80%+154.96%+205.76%

Financials

2026 *2027 *
Net sales 2.72M 2.38M 2.24M 2.04M 3.82M 261M 3.83M 26.86M 10.37M 133M 10.23M 10M 428M 9.27M 8.09M 7.64M 6.93M 12.99M 890M 13.05M 91.47M 35.3M 452M 34.84M 34.07M 1.46B
Net income -22.25M -19.4M -18.32M -16.64M -31.17M -2.14B -31.3M -219M -84.69M -1.09B -83.59M -81.73M -3.49B -18.42M -16.06M -15.17M -13.77M -25.8M -1.77B -25.91M -182M -70.1M -899M -69.19M -67.65M -2.89B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
18/09/26 US$0.2600 -8.74% 4,368,077
17/09/26 US$0.2849 +3.64% 28,229,427
16/09/26 US$0.2749 -4.98% 1,436,042
15/09/26 US$0.2893 -7.31% 2,180,179
14/09/26 US$0.3121 +0.61% 2,361,493
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2600USD
Average target price
13.62USD
Spread / Average Target
+5,139.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!